The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Diarrhea, Medullary Thyroid Cancer

In brief

Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. Diarrhea can also lead to increased cost of care, reduced quality of life, and treatment delays. Not all patients benefit from conventional anti-diarrheal therapy. CASAD is proven to reduce diarrhea in humans and animals. Clays have water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb the excess cytokines which are possible mechanisms of diarrhea in MTC. In this study, we will investigate if starting 1 g CASAD three times a day will ameliorate the severity of diarrhea in patients with MTC. Diarrhea in patients with MTC can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. We hypothesize that adding CASAD 3 grams/day will reduce the incidence and ameliorate the severity of diarrhea in patients with MTC.

Key facts

Study ID

NCT01739634

Run by

Salient Pharmaceuticals Incorporated

People needed

10

Starts

2012-11-01

Expected to finish

2013-12-01

Last updated by the study team

2012-12-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with medullary thyroid cancer
• Men and women from all ethnic and racial groups
• Diarrhea ( >=3 loose bowel movements per day)
• Duration of diarrhea of at least 1 week

You may not qualify if…

• Patients with MEN 2b (since these patients may have megacolon)
• Patients taking any clay products
• History of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up.
• Patients who cannot comply with medications
• Patients whose current medication schedule would not permit an approximate 2 hour window between administration of CASAD and other scheduled medications.
• Pregnancy or lactation
• Patients receiving systemic chemotherapy (includes tyrosine kinase inhibitors)

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.